The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*
Open accessAbstract
OBJECTIVE: To determine the efficacy of anakinra (recombinant interleukin-1 receptor antagonist) in improving 28-day survival in sepsis patients with features of macrophage activation syndrome. Despite equivocal results in sepsis trials, anakinra is effective in treating macrophage activation syndrome, a similar entity with fever, disseminated intravascular coagulation, hepatobiliary dysfunction, cytopenias, and hyperferritinemia. Hence, sepsis patients with macrophage activation syndrome features may benefit from interleukin-1 receptor blockade. DESIGN: Reanalysis of deidentified data from the phase III randomized interleukin-1 receptor antagonist trial in severe sepsis. SETTING: Multicenter study recruiting through 91 centers from 11 countries in Europe and North America. PATIENTS: Sepsis patients with multiorgan dysfunction syndrome and/or shock (original study) were regrouped based on the presence or the absence of concurrent hepatobiliary dysfunction and disseminated intravascular coagulation as features of macrophage activation syndrome. The non-hepatobiliary dysfunction/disseminated intravascular coagulation group included patients with only hepatobiliary dysfunction, only disseminated intravascular coagulation, or neither. INTERVENTION: Treatment with anakinra or placebo. MEASUREMENTS AND MAIN RESULTS: Main outcome was 28-day mortality. Descriptive and comparative statistics were performed. Data were available for 763 adults from the original study cohort, randomized to receive either anakinra or placebo. Concurrent hepatobiliary dysfunction/disseminated intravascular coagulation was noted in 43 patients (5.6% of total; 18-75 years old; 47% women). The 28-day survival was similar in both anakinra and placebo-treated non-hepatobiliary dysfunction/disseminated intravascular coagulation patients (71.4% vs 70.8%; p = 0.88). Treatment with anakinra was associated with significant improvement in the 28-day survival rate in hepatobiliary dysfunction/disseminated intravascular coagulation patients (65.4% anakinra vs 35.3% placebo), with hazard ratio for death 0.28 (0.11-0.71; p = 0.0071) for the treatment group in Cox regression. CONCLUSIONS: In this subgroup analysis, interleukin-1 receptor blockade was associated with significant improvement in survival of patients with sepsis and concurrent hepatobiliary dysfunction/disseminated intravascular coagulation. A prospective randomized trial using features of macrophage activation syndrome for mortality risk stratification should be undertaken to confirm the role of interleukin-1 blockage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, reanalysis of a negative trial of interleukin-1β blockade in patients with sepsis identified a subgroup of patients with elevated ferritin levels who seemed to benefit from the treatment.63”
From Cytokine storm (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E. H., Angus, D. C., Cook, D., Cohen, J., Opal, S. M., Vincent, J., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,976
Self-citationThe Pathophysiology and Treatment of Sepsis
Hotchkiss, R. S., & Karl, I. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021333 · Cited by 4,132
An Expanded Definition of the Adult Respiratory Distress Syndrome
Murray, J. F., Matthay, M. A., Luce, J. M., & Flick, M. R. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.3.720 · Cited by 2,641
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citationTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,810
Self-citationFardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., Coppo, P., & Hejblum, G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38690 · Cited by 1,508
Interleukin-1 and the Pathogenesis of the Acute-Phase Response
Epstein, F. H., & Dinarello, C. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411293112205 · Cited by 1,151
Self-citationConfirmatory interleukin-1 receptor antagonist trial in severe sepsis
Opal, S. M., Fisher, C. J., Dhainaut, J.-F., Vincent, J., Brase, R., Lowry, S. F., SADOFF, J. C., Slotman, G. J., Levy, H. A., BALK, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 882
Self-citationHighly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis
Allen, C. E., Yu, X., Kozinetz, C. A., & McClain, K. L. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21423 · Cited by 637
Research works printed but not linked: 4
- Emmenegger, 2005, Swiss Med Wkly, 135, 299
- Behrens, 2007, J Rheumatol, 34, 1133
- Behrens, 2006, J Rheumatol, 33, 2081
- Marti-Carvajal, 2012, Cochrane Database Syst Rev, 12, CD004388
Cited by
Sorted by citations
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Self-citationRecommendations for the management of hemophagocytic lymphohistiocytosis in adults
Rosée, P. G. L., Horne, A., Hines, M., Greenwood, T. V. B., Machowicz, R., Berliner, N., Birndt, S., Gil-Herrera, J., Girschikofsky, M., Jordan, M. B., et al. (2019) · Blood · doi:10.1182/blood.2018894618 · Cited by 1,127
van der Poll, T., Shankar‐Hari, M., & Wiersinga, W. J. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.012 · Cited by 1,094
Advances in the understanding and treatment of sepsis-induced immunosuppression
Venet, F., & Monneret, G. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.165 · Cited by 1,021
Cavalli, G., Luca, G. D. D., Campochiaro, C., Della‐Torre, E., Ripa, M., Canetti, D., Oltolini, C., Castiglioni, B., Din, C. T., Boffini, N., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30127-2 · Cited by 977
Myocardial Localization of Coronavirus in COVID-19 Cardiogenic Shock
Tavazzi, G., Pellegrini, C., Maurelli, M., Belliato, M., Sciutti, F., Bottazzi, A., Sepe, P. A., Resasco, T., Camporotondo, R., Bruno, R., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1828 · Cited by 932
Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. F. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 869
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment
Soy, M., Keser, G., Atagündüz, P., Tabak, F., Atagündüz, I., & Kayhan, S. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05190-5 · Cited by 837
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S. A., Marchetti, C., Kron, J., Tassell, B. W. V., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 760
Self-citationImmunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 719
Cytokine storms: understanding COVID-19
Mangalmurti, N., & Hunter, C. A. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.017 · Cited by 698
Zeidan, A. M., Boddu, P. C., Patnaik, M. M., Bewersdorf, J. P., Stahl, M. F., Rampal, R. K., Shallis, R. M., Steensma, D. P., Savona, M. R., Sekeres, M. A., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30205-2 · Cited by 675
COVID-19: Immunology and treatment options
Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108448 · Cited by 686
Jamilloux, Y., Henry, T., Bélot, A., Viel, S., Fauter, M., Jammal, T. E., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 661
Anakinra for severe forms of COVID-19: a cohort study
Huet, T., Beaussier, H., Voisin, O., Jouveshomme, S., Dauriat, G., Lazareth, I., Sacco, E., Naccache, J., Bézie, Y., Laplanche, S., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30164-8 · Cited by 651
On the Alert for Cytokine Storm: Immunopathology in COVID ‐19
Henderson, L. A., Canna, S., Schulert, G. S., Volpi, S., Lee, P. Y., Kernan, K. F., Caricchio, R., Mahmud, S. A., Hazen, M. M., Halyabar, O., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41285 · Cited by 651
Self-citationRathkey, J. K., Zhao, J., Liu, Z., Chen, Y., Yang, J., Kondolf, H. C., Benson, B. L., Chirieleison, S. M., Huang, A. Y.-C., Dubyak, G., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat2738 · Cited by 618
The role of interleukin-1 in general pathology
Kaneko, N., Kurata, M., Yamamoto, T., Morikawa, S., & Masumoto, J. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0101-5 · Cited by 642
Hyperferritinemia and inflammation
Kernan, K. F., & Carcillo, J. A. (2017) · International Immunology · doi:10.1093/intimm/dxx031 · Cited by 638
Self-citationImmunopathology of Hyperinflammation in COVID-19
Gustine, J. N., & Jones, D. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.08.009 · Cited by 516
Henderson, L. A., Canna, S., Friedman, K. G., Gorelik, M., Lapidus, S., Bassiri, H., Behrens, E. M., Ferris, A. M., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41454 · Cited by 540
Nakra, N. A., Blumberg, D. A., Herrera-Guerra, A., & Lakshminrusimha, S. (2020) · Children · doi:10.3390/children7070069 · Cited by 523
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
Tufan, A., Güler, A. A., & Matucci‐Cerinic, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-168 · Cited by 501
Immunopathogenesis and treatment of cytokine storm in COVID-19
Kim, J., Lee, J. Y., Yang, J. W., Lee, K. H., Effenberger, M., Szpirt, W. M., Kronbichler, A., & Shin, J. I. (2020) · Theranostics · doi:10.7150/thno.49713 · Cited by 477
Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L. P., Kyriakidis, N. C., Muslin, C., Jaramillo, A. M. G., Barba-Ostria, C., Cevallos-Robalino, D., et al. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115094 · Cited by 458
COVID-19 infection and rheumatoid arthritis: Faraway, so close
Favalli, E. G., Ingegnoli, F., De Lucia, O., Cincinelli, G., Cimaz, R., & Caporali, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102523 · Cited by 454
Menopausal changes in bone remodeling.
Heaney, R. P., Recker, R. R., & Saville, P. D. (1978) · PubMed · Cited by 435
Jordan, M. B., Allen, C. E., Greenberg, J., Henry, M., Hermiston, M. L., Kumar, A. R., Hines, M., Eckstein, O. S., Ladisch, S., Nichols, K. E., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27929 · Cited by 428
Henderson, L. A., Canna, S., Friedman, K. G., Gorelik, M., Lapidus, S., Bassiri, H., Behrens, E. M., Ferris, A. M., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41616 · Cited by 431
Multi-organ proteomic landscape of COVID-19 autopsies
Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.004 · Cited by 403
Targeting the NLRP3 Inflammasome in Severe COVID-19
Freeman, T. L., & Swartz, T. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01518 · Cited by 413
Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03279 · Cited by 421
Weiss, E. S., Girard-Guyonvarc’h, C., Holzinger, D., de Jesus, A. A., Tariq, Z., Picarsic, J. L., Schiffrin, E. J., Foell, D., Grom, A. A., Ammann, S., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820852 · Cited by 406
Zhang, D., Guo, R., Lei, L., Liu, H., Wang, Y., Wang, Y., Qian, H., Dai, T., Zhang, T., Lai, Y., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4hi0720-470r · Cited by 395
The pathophysiology of sepsis and precision-medicine-based immunotherapy
Giamarellos‐Bourboulis, E. J., Aschenbrenner, A. C., Bauer, M. W., Bock, C., Calandra, T., Gat‐Viks, I., Kyriazopoulou, E., Lupșe, M. S., Monneret, G., Pickkers, P., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01660-5 · Cited by 399
Sweeney, T. E., Azad, T. D., Donato, M., Haynes, W. A., Perumal, T. M., Henao, R., Bermejo-Martín, J. F., Almansa, R., Tamayo, E., Howrylak, J. A., et al. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003084 · Cited by 376
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 384
Self-citationSignaling pathways and intervention therapies in sepsis
Zhang, Y., & Ning, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00816-9 · Cited by 369
Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies
Ojo, A. S., Balogun, S. A., Williams, O. T., & Ojo, O. S. (2020) · Pulmonary Medicine · doi:10.1155/2020/6175964 · Cited by 376
Cavalli, G., Colafrancesco, S., Emmi, G., Imazio, M., Lopalco, G., Maggio, M. C., Sota, J., & Dinarello, C. A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102763 · Cited by 368
Self-citationAn immune-based biomarker signature is associated with mortality in COVID-19 patients
Abers, M. S., Delmonte, O. M., Ricotta, E., Fintzi, J., Fink, D. L., de Jesus, A. A., Zarember, K. A., Alehashemi, S., Oikonomou, V., Desai, J. V., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.144455 · Cited by 345
Self-citationCOVID-19 and the Immune System
Pačes, J., Strizova, Z. O., Smrž, D., & Černý, J. (2020) · Physiological Research · doi:10.33549/physiolres.934492 · Cited by 353
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Zhang, Q., Xiang, R., Huo, S., Zhou, Y., Jiang, S., Wang, Q., & Yu, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00653-w · Cited by 364
Sepsis therapies: learning from 30 years of failure of translational research to propose new leads
Cavaillon, J., Singer, M., & Skirecki, T. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201810128 · Cited by 330
IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections
Slaats, J., ten Oever, J., van de Veerdonk, F. L., & Netea, M. G. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005973 · Cited by 331
Cytokine Storm—Definition, Causes, and Implications
Jarczak, D., & Nierhaus, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911740 · Cited by 336
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 307
Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis
Karakike, E., & Giamarellos‐Bourboulis, E. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00055 · Cited by 304
COVID-19 and immunomodulation in IBD
Neurath, M. F. (2020) · Gut · doi:10.1136/gutjnl-2020-321269 · Cited by 305
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 305
Self-citationRahman, S., Montero, M. T. V., Rowe, K., Kirton, R., & Kunik, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1902303 · Cited by 315
Pharmaco-Immunomodulatory Therapy in COVID-19
Rizk, J. G., Kalantar‐Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020) · Drugs · doi:10.1007/s40265-020-01367-z · Cited by 298
Mehta, P., Cron, R. Q., Hartwell, J., Manson, J. J., & Tattersall, R. S. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30096-5 · Cited by 291
Self-citationTharaux, P., Pialoux, G., Pavot, A., Mariette, X., Hermine, O., Resche‐Rigon, M., Porcher, R., Ravaud, P., Bureau, S., Dougados, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30556-7 · Cited by 295
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Eloseily, E. M., Weiser, P., Crayne, C. B., Haines, H., Mannion, M. L., Stoll, M. L., Beukelman, T., Atkinson, T. P., & Cron, R. Q. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41103 · Cited by 282
Self-citationImmune dysregulation in sepsis: experiences, lessons and perspectives
Cao, M., Wang, G., & Xie, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01766-7 · Cited by 284
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
Copaescu, A. M., Smibert, O. C., Gibson, A., Phillips, E. J., & Trubiano, J. A. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.001 · Cited by 263
Carter, S. J., Tattersall, R. S., & Ramanan, A. V. (2018) · Rheumatology · doi:10.1093/rheumatology/key006 · Cited by 265
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation
Silva, C. M. S., Wanderley, C. W. S., Veras, F. P., Sônego, F., Nascimento, D. C., Gonçalves, A. V., Martins, T. V., Colón, D. F., Borges, V. F., Brauer, V. S., et al. (2021) · Blood · doi:10.1182/blood.2021011525 · Cited by 270
Inflammasomes in Tissue Damages and Immune Disorders After Trauma
Bortolotti, P., Faure, E., & Kipnis, É. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01900 · Cited by 267
Manson, J. J., Crooks, C. J., Naja, M., Ledlie, A., Goulden, B., Liddle, T., Khan, E., Mehta, P., Martin‐Gutierrez, L., Waddington, K. E., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30275-7 · Cited by 289
Dimopoulos, G., de Mast, Q., Μάρκου, Ν., Θεοδωρακοπούλου, Μ., Komnos, A., Mouktaroudi, M., Netea, M. G., Spyridopoulos, T. N., Verheggen, R. J. H. M., Hoogerwerf, J. J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.007 · Cited by 245
Cajander, S., Kox, M., Scicluna, B. P., Weigand, M. A., Mora, R. A., Flohé, S. B., Martín‐Loeches, I., Lachmann, G., Girardis, M., García‐Salido, A., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00330-2 · Cited by 248
Subphenotypes in critical care: translation into clinical practice
Reddy, K., Sinha, P., O’Kane, C. M., Gordon, A. C., Calfee, C. S., & McAuley, D. F. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30124-7 · Cited by 238
The immunology of COVID-19: is immune modulation an option for treatment?
Zhong, J., Tang, J., Ye, C., & Dong, L. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30120-x · Cited by 241
Alijotas‐Reig, J., Esteve‐Valverde, E., Belizna, C. C., Selva-O’Callaghan, A., Pardos‐Gea, J., Quintana, Á., MEKINIAN, A., Anunciación-Llunell, A., & Miró‐Mur, F. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102569 · Cited by 238
Fautrel, B., Mitrovic, S., Matteis, A. D., Bindoli, S., Antón, J., Bélot, A., Bracaglia, C., Constantin, T., Dagna, L., Bartolo, A. D., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-225851 · Cited by 232
Korakas, E., Ikonomidis, I., Kousathana, F., Balampanis, K., Kountouri, A., Raptis, A. E., Palaiodimou, L., Kokkinos, A. D., & Lambadiari, V. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00198.2020 · Cited by 226
Hemophagocytic Lymphohistiocytosis
Henter, J. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2314005 · Cited by 221
Macrophage Activation Syndrome
Ravelli, A., Davì, S., Minoia, F., Martini, A., & Cron, R. Q. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.06.010 · Cited by 211
Self-citationon behalf of the Hellenic Sepsis Study Group, Kyriazopoulou, E., Leventogiannis, K., Norrby‐Teglund, A., Dimopoulos, G., Pantazi, A., Orfanos, S. E., Rovina, N., Tsangaris, I., Gkavogianni, T., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0930-5 · Cited by 212
The immune response to SARS-CoV-2 and COVID-19 immunopathology – Current perspectives
Boechat, J. L., Chora, I., Morais, A., & Delgado, L. (2021) · Pulmonology · doi:10.1016/j.pulmoe.2021.03.008 · Cited by 225
Vincent, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104318 · Cited by 222
Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review
Ahmed, M. U., Hanif, M., Ali, M. J., Haider, M. A., Kherani, D., Memon, G. M., Karim, A. H., & Sattar, A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00518 · Cited by 218
T‐cell responses and therapies against SARS‐CoV‐2 infection
Toor, S. M., Saleh, R., Nair, V. S., Taha, R. Z., & Elkord, E. (2020) · Immunology · doi:10.1111/imm.13262 · Cited by 208
Banu, N., Panikar, S. S., Leal, L. R., & Leal, A. R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117905 · Cited by 212
Tleyjeh, I. M., Kashour, Z., Damlaj, M., Riaz, M. A., Tlayjeh, H., Altannir, M., Altannir, Y., Al-Tannir, M. A., Tleyjeh, R., Hassett, L. C., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.036 · Cited by 205
Strati, P., Ahmed, S., Kebriaei, P., Nastoupil, L. J., Claussen, C. M., Watson, G., Horowitz, S. B., Brown, A. R., Do, B., Rodriguez, M. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002328 · Cited by 202
Cytokine storm syndrome in coronavirus disease 2019: A narrative review
Gao, Y.-M., Xu, G., Wang, B., & Liu, B. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13144 · Cited by 204
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19
Cauchois, R., Koubi, M., Delarbre, D., Manet, C., Carvelli, J., Blasco, V., Jean, R., Fouché, L., Bornet, C., Pauly, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009017117 · Cited by 199
Self-citationNeutrophil pyroptosis: new perspectives on sepsis
Liu, L., & Sun, B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03060-1 · Cited by 200
Alternative Pathways of IL-1 Activation, and Its Role in Health and Disease
Pyrillou, K., Burzynski, L. C., & Clarke, M. C. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613170 · Cited by 199
Monteagudo, L., Boothby, A. B., & Gertner, E. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11135 · Cited by 184
Controlling Cytokine Storm Is Vital in COVID-19
Tang, L., Yin, Z., Hu, Y., & Mei, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570993 · Cited by 183
Sepsis and Immunosenescence in the Elderly Patient: A Review
Martín, S., Pérez, A. I. B., & Aldecoa, C. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00020 · Cited by 184
Interleukin-1 Family Cytokines: Keystones in Liver Inflammatory Diseases
Barbier, L. A., Ferhat, M., Salamé, E., Robin, A., Herbelin, A., Gombert, J., Silvain, C., & Barbarin, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02014 · Cited by 178
Azithromycin in viral infections
Oliver, M., & Hinks, T. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2163 · Cited by 181
Cavalli, G., Larcher, A., Tomelleri, A., Campochiaro, C., Della‐Torre, E., Luca, G. D. D., Farina, N., Boffini, N., Ruggeri, A., Poli, A., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00012-6 · Cited by 173
Sandler, R. D., Tattersall, R. S., Schoemans, H. M., Greco, R., Badoglio, M., Labopin, M., Alexander, T., Киргизов, К. И., Rovira, M., Saif, M. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00524 · Cited by 171
Systemic Juvenile Idiopathic Arthritis
Lee, J. J. Y., & Schneider, R. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.04.005 · Cited by 175
Seymour, C. W., Gómez, H., Chang, C. H., Clermont, G., Kellum, J. A., Kennedy, J. N., Yende, S. P., & Angus, D. C. (2017) · Critical Care · doi:10.1186/s13054-017-1836-5 · Cited by 173
Henderson, L. A., & Cron, R. Q. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00367-1 · Cited by 168
Self-citationIngraham, N. E., Lotfi‐Emran, S., Thielen, B. K., Techar, K., Morris, R., Holtan, S. G., Dudley, R. A., & Tignanelli, C. J. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30226-5 · Cited by 166
Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality
Que, Y., Hu, C., Wan, K., Hu, P., Wang, R., Luo, J., Li, T., Ping, R., Hu, Q., Sun, Y., et al. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1884248 · Cited by 167
Targeting Immune Cell Checkpoints during Sepsis
Patil, N. K., Guo, Y., Luan, L., & Sherwood, E. R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112413 · Cited by 174
Precision Immunotherapy for Sepsis
van Ton, A. M. P., Kox, M., Abdo, W. F., & Pickkers, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01926 · Cited by 167
Kyriazopoulou, E., Huet, T., Cavalli, G., Gori, A., Kyprianou, M., Pickkers, P., Eugen‐Olsen, J., Clerici, M., Veas, F., Châtellier, G., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00216-2 · Cited by 163
Metadata
- Authors
- Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M.
- Affiliations
- George Washington University (US)
- University of Pittsburgh Medical Center (US)
- University of Alabama at Birmingham (US)
- Temple University (US)
- University of Colorado Anschutz (US)
- Brown University (US)
- ORCID
- Venue
- Critical Care Medicine
- Published
- 2016-02
- Volume
- 44
- Issue
- 2
- Pages
- 275-281
- ISSN
- 0090-3493 (ISSN-L)
- PMC
- PMC5378312
- OpenAlex
- W2177407033
- Cited by
- 867
- References
- 48
- Citations by year
- 2026: 66 · 2025: 64 · 2024: 68 · 2023: 76 · 2022: 87 · 2021: 141 · 2020: 226 · 2019: 43 · 2018: 36 · 2017: 42 · 2016: 15
- FWCI
- 24.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM108618)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
- Keywords
- sepsis, anakinra, interleukin-1 receptor antagonist, interleukin-1 blockade, 28-day mortality, hepatobiliary dysfunction, disseminated intravascular coagulation, multiple organ failure, septic shock, subgroup analysis, hyperferritinemia, cytokine storm
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Biliary Tract Diseases, Disseminated Intravascular Coagulation, Double-Blind Method, Female, Humans, Liver Diseases, Male, Middle Aged, Multiple Organ Failure, Respiratory Distress Syndrome, Sex Factors, Shock, Septic, Receptors, Interleukin-1, Sepsis, APACHE, Interleukin 1 Receptor Antagonist Protein, Macrophage Activation Syndrome, Young Adult, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
